Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed recurrent or metastatic squamous cell carcinoma of the head and neck.~* Recurrent/metastatic disease not amenable to surgery or salvage chemoradiation.~* Unidimensional measurable disease according to the RECIST~* In-field recurrence, within a prior radiation field only, distant metastatic disease~* Both in-field and metastatic sites of disease will require evaluation by a Radiation Oncologist to consider local radiation therapy first and will be eligible for possible enrollment one month after completion of the radiation therapy.~* Negative pregnancy test~* Patients may have received prior chemotherapy as part of chemoradiation or induction chemotherapy for initial treatment of disease confined to the head and neck region - Patients must have fully recovered from any prior radiation therapy~Exclusion Criteria:~* Patients who have relapsed \< 6 months after completing a combined modality curative treatment that included a fluoropyrimidine or taxanes~* No brain metastases~* No major neurological disease, including stroke~* No prior chemotherapy regimen for recurrent/metastatic disease~* No prior history of capecitabine usage~* No prior history of docetaxel usage except in the induction setting for head and neck cancer which has been completed for greater than 6 months prior to beginning protocol therapy~* No past hypersensitivity to taxanes or 5 FU~* No hypersensitivity to docetaxel or other drugs formulated with polysorbate 80~* No current use of warfarin~* Patients must not be receiving ketoconazole, midazolam, erythromycin, orphenadrine, troleandomycin, cyclosporine or antiepileptics~* Patients must not be treated with any of the following on protocol therapy or within 28 days prior to beginning protocol therapy: sorivudine, brivudine, cimetidine, allopurinol~* Patients must have fully recovered from any prior surgery~* No known HIV seropositivity.~* No serious uncontrolled medical condition, uncontrolled peptic ulcer disease or malabsorption syndrome~* No peripheral neuropathy \> grade 1~* Patients with a percutaneous gastrostomy (PEG) must be able take medications by tube.~* No daily consumption of alcohol~* No active infection~* No prior history of malignancy in the last 5 years, excluding in situ carcinoma of the cervix or adequately treated basal or squamous cell carcinoma of the skin or Gleason Grade \< VII organ confined prostate cancer.~* No current breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Docetaxel + Capecitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy